Key Highlights
- Charles Baum, M.D., Ph.D., appointed as Chief Executive Officer of Terremoto Biosciences.
- Baum succeeds Peter Thompson, who remains as Board chairperson.
- Baum’s previous leadership at Mirati Therapeutics led to significant pipeline value and a major acquisition.
- Terremoto focuses on developing highly targeted therapeutics for severe diseases.
- Baum’s extensive drug development experience includes work at Pfizer and Schering Plough.
Source: Business Wire
Notable Quotes
- “Chuck has a legacy of successful leadership in precision therapeutics, most recently at Mirati Therapeutics, where under his guidance, the company was transformed and went on to create compelling pipeline value that led to an acquisition by Bristol Meyers Squibb for up to $5.8 billion.” — Dr. Peter Thompson, Chairperson of the Board at Terremoto Biosciences
- “Terremoto’s compelling science and innovative approach to developing and advancing groundbreaking medicines creates an unmatched opportunity to fundamentally change the treatment paradigm for people with devastating diseases.” — Dr. Charles Baum, Chief Executive Officer (CEO) at Terremoto Biosciences
SoHC's Take
The appointment of Charles Baum as CEO of Terremoto Biosciences marks a significant milestone for the company. Baum’s impressive track record in drug development and leadership, particularly his transformative role at Mirati Therapeutics, positions him as an ideal leader to advance Terremoto’s mission. His experience in developing major oncology drugs at Pfizer and Schering Plough will be invaluable as Terremoto continues to innovate in creating highly targeted therapeutics for severe diseases. Under Baum’s leadership, Terremoto is well-positioned to make significant strides in delivering groundbreaking medicines that address critical unmet needs in the medical field.
